FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Regeneron and Sanofi announced the FDA has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis in adults whose disease is not controlled. CRSwNP often occurs in combination with severe asthma. June 26, 2019